Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma-Reference-Cited by-同舟云学术

Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma

Published:2018 Issue:17 Volume:10 Page:8207-8216
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Xiao Kai¹²³⁴⁵^ORCID,Liu Qiangqiang¹²³⁴⁵,Al Awwad Nasir⁶⁷⁸⁹¹⁰,Zhang Hongyong¹¹¹²¹³⁸¹⁰,Lai Li¹²³⁴⁵,Luo Yan⁶⁷⁸⁹¹⁰,Lee Joyce S.⁶⁷⁸⁹¹⁰,Li Yuanpei⁶⁷⁸⁹¹⁰^ORCID,Lam Kit S.⁶⁷⁸⁹¹⁰

Affiliation:

1. National Chengdu Center for Safety Evaluation of Drugs

2. State Key Laboratory of Biotherapy

3. Collaborative Innovation Center for Biotherapy

4. West China Hospital

5. Sichuan University

6. Department of Biochemistry & Molecular Medicine

7. UC Davis Cancer Center

8. University of California Davis

9. Sacramento

10. USA

11. Division of Hematology & Oncology

12. Department of Internal Medicine

13. School of Medicine

Abstract

Disulfide cross-linked micellar formulation significantly improved the pharmacokinetics, tumor targeting, and anti-tumor efficacy of doxorubicin against B-cell lymphoma.

Funder

National Institutes of Health

U.S. Department of Defense

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2018/NR/C8NR00680F

Reference35 articles.

1. Adriamycin-induced myocardial toxicity: New solutions for an old problem?